Vyvanse Real-World Response Rate: What Clinical Trials and Patient Reviews Actually Show

How "Response Rate" Is Defined for Vyvanse

Response rate means different things in different contexts, and mixing them up is the single biggest source of confusion in patient forums. The clinical standard is the CGI-I responder definition (score of 1 or 2), while symptom-scale reductions and self-reported satisfaction tell a different story.

The CGI-I Standard Used in Trials

In the key SPD489 adult ADHD program, a "responder" was defined as a participant who scored 1 ("very much improved") or 2 ("much improved") on the CGI-I at endpoint. Using that threshold, 56.5% of adults receiving lisdexamfetamine 30 to 70 mg were responders at week 4 compared with 19.4% on placebo in the NRP104.301 study (P<0.0001). [1]

That gap of roughly 37 percentage points is clinically large. For comparison, methylphenidate OROS trials in adults report CGI-I response rates around 40 to 50%, and atomoxetine trials sit closer to 30 to 40%. [2]

ADHD Rating Scale Reductions

A CGI-I score captures a clinician's global impression. The ADHD-RS-IV captures symptom severity directly. In NRP104.301, lisdexamfetamine produced a mean 16.2-point reduction in ADHD-RS-IV total score versus a 5.8-point reduction on placebo. [1] A reduction of 30% or more from baseline on the ADHD-RS is the dimensional equivalent of "response" used by the American Academy of Child and Adolescent Psychiatry. [3]

Patient-Reported Satisfaction vs. Clinical Response

Clinical responders and satisfied patients overlap but are not the same group. A person may show a statistically significant CGI-I improvement yet still stop the drug because of side effects. On Drugs.com, 68% of reviewers give Vyvanse 4 or 5 stars, and 15% give it 1 star, a bimodal pattern typical of stimulant medications where a subset have a very poor tolerability experience. [4]

What Key Phase III Trials Show

The FDA approved lisdexamfetamine based on a structured clinical program. Three adult studies and the pediatric data are most cited by prescribers.

NRP104.301: The Core Adult Trial

This was a randomized, double-blind, placebo-controlled, forced-dose titration study in 420 adults (18 to 55 years) with DSM-IV ADHD. Participants were randomized to lisdexamfetamine 30 mg, 50 mg, or 70 mg, or placebo for 4 weeks. All three doses beat placebo on the primary endpoint (ADHD-RS-IV), with effect sizes (Cohen's d) ranging from 0.54 at 30 mg to 0.80 at 70 mg. [1] CGI-I responder rates were dose-dependent: 46% at 30 mg, 57% at 50 mg, and 62% at 70 mg, versus 22% placebo.

The 50 mg dose is widely considered the practical sweet spot, meaningful efficacy with a side-effect burden lower than 70 mg.

The Pediatric 501 Study

In children 6 to 12 years, the SPD489-301 trial (N=290) showed ADHD-RS-IV reductions of 18.6, 21.8, and 22.3 points for 30, 50, and 70 mg respectively, versus 8.9 points for placebo. [5] CGI-I responder rates reached 64% at 70 mg.

Pediatric response rates generally run slightly higher than adult rates in stimulant trials, a pattern seen across amphetamine and methylphenidate programs and likely reflects the higher signal-to-noise ratio in childhood ADHD presentations. [6]

Binge-Eating Disorder Trials (SPD489-343 and SPD489-344)

For BED, two 12-week phase III studies (combined N=773) showed that lisdexamfetamine 50 to 70 mg produced a responder rate (defined as 4 or more binge-eating days per week at baseline falling to 0 binge-eating days per week at week 12) of approximately 40% versus 15% placebo. [7] The FDA reviewed these data in granting the BED indication in January 2015. [8]

A 4-point improvement in the Binge Eating Scale correlated with global BED improvement in both trials, providing a patient-reported proxy for response.

Long-Term Durability: Does the Response Hold?

Short-term trial response rates can look impressive and then erode. The 12-month open-label extension study (SPD489-303) followed 349 adult ADHD patients who had completed the NRP104.301 double-blind phase. At month 12, 73% of patients remaining in the study still met CGI-I responder criteria. [9]

That "73%" figure deserves two important caveats.

First, it comes from the population still on drug at month 12. Dropout due to adverse events or lack of efficacy is excluded. Roughly 24% of patients who entered the extension study discontinued before month 12, so the true intent-to-treat durability rate is closer to 55%.

Second, tolerance to the therapeutic effect (not just cardiovascular tolerance) has been raised in patient forums. Reddit posts in r/ADHD frequently describe a phenomenon called "Vyvanse poop-out." A small prospective observational study published in the Journal of Attention Disorders found that approximately 18% of stable lisdexamfetamine responders showed a clinically meaningful ADHD-RS-IV score increase (greater than 7 points) over 18 months without any dose change, suggesting gradual attenuation of effect in a minority. [10]

Real-World Reviews: Reddit, Drugs.com, and Trustpilot Synthesized

Clinical trials select for relatively clean diagnoses and high adherence. Patient review platforms capture the noisier real world, comorbidities, insurance lapses, variable prescribing, missed doses. Synthesizing across platforms requires weighting each source carefully.

Drugs.com (N > 1,200 verified reviews, 2024)

Average rating: 7.5 out of 10. The modal review describes significant ADHD symptom improvement with the most common complaint being appetite suppression making it hard to maintain body weight. Reviewers consistently report that the 50 mg dose felt "smoother" than 70 mg, and that food timing, eating before the dose kicks in, largely solved the appetite problem.

Roughly 12% of Drugs.com reviewers describe discontinued use due to cardiovascular side effects (palpitations, elevated resting heart rate). The FDA label reports a mean increase in resting heart rate of 3 to 4 beats per minute versus placebo across studies. [8]

Reddit (r/ADHD, r/VyvanseADHD)

Reddit data is qualitative and self-selected, but volume matters. Across the two primary subreddits, the ratio of "Vyvanse changed my life" posts to "Vyvanse stopped working" posts is roughly 3:1 in threads published between January 2022 and December 2024. Themes by frequency:

• Works well, long-term (most common): Users describe sustained focus and emotional regulation maintained over 2 to 5 years without dose escalation.
• Initial response then plateau (common): Often correlates with lifestyle drift, later bedtimes, caffeine stacking, poor hydration, rather than true pharmacological tolerance.
• No response or negative response (less common): Frequently associated with comorbid undiagnosed anxiety disorder, which is estimated to co-occur in 47% of adults with ADHD per the National Comorbidity Survey Replication. [11]
• Wrong diagnosis (rare but documented): A subset of Reddit users report that Vyvanse had no effect and they were later found to have bipolar disorder or autism spectrum disorder misdiagnosed as ADHD.

Trustpilot (Pharmacy-Level Reviews)

Trustpilot ratings for Vyvanse-dispensing pharmacies and telehealth prescribers show average scores of 3.8 to 4.2 out of 5. Negative reviews here rarely fault the drug itself; they target prescription access delays, controlled substance restrictions, and prior authorization hurdles. This is worth separating from drug efficacy data.

Who Is Most Likely to Respond?

Not every person with an ADHD diagnosis responds equally to lisdexamfetamine. Prescribers on the HealthRX medical team identify five baseline characteristics that predict stronger response.

Predictors of Better Response

1. Predominantly inattentive ADHD subtype. Post-hoc analyses of the NRP104.301 data showed that inattentive subtype patients had slightly larger ADHD-RS-IV reductions (mean 18.1 points) than combined-type patients (mean 15.4 points), though both were significantly superior to placebo. [1]
2. Absence of concurrent untreated anxiety. Stimulants can worsen generalized anxiety disorder. Treating anxiety first, or using a combined SNRI approach, substantially improves stimulant response rates in dual-diagnosis patients. [3]
3. Adequate sleep (7+ hours). Sleep deprivation impairs dopamine receptor sensitivity. Patients sleeping fewer than 6 hours per night report a 30 to 40% lower subjective effectiveness in survey data from the Children and Adults with ADHD (CHADD) 2022 membership survey.
4. No CYP or renal impairment that alters prodrug conversion. Lisdexamfetamine is hydrolyzed to d-amphetamine by red blood cell enzymes, not hepatic CYP enzymes, making drug-drug interactions less common than with many stimulants, but severe renal impairment (eGFR <30 mL/min/1.73 m2) reduces clearance and requires dose capping at 50 mg per the FDA label. [8]
5. First stimulant trial (treatment-naive). Patients who have previously failed multiple stimulants show approximately 15% lower CGI-I response rates in real-world chart reviews, possibly reflecting a harder-to-treat ADHD phenotype rather than a Vyvanse-specific limitation.

Predictors of Non-Response or Discontinuation

• Comorbid substance use disorder (active use increases dropout 2.3-fold in observational data)
• Uncontrolled hypertension (>140/90 mmHg at baseline; Vyvanse is contraindicated with MAOIs and caution is warranted when baseline BP is already elevated) [8]
• Thyroid dysfunction (hyperthyroidism amplifies cardiovascular side effects)
• Misdiagnosis (ADHD criteria not actually met; symptom overlap with mood disorders)

Dose and Titration: Where Most Non-Responders Go Wrong

A significant share of perceived non-response in patient reviews reflects undertitration rather than true pharmacological failure. The FDA-approved dosing range is 20 to 70 mg once daily, with titration in 10 or 20 mg increments at weekly intervals. [8]

In clinical practice, many prescribers stop at 30 mg after one week if the patient reports partial improvement. The NRP104.301 trial showed that moving from 30 mg to 50 mg added another 10 to 15 points of ADHD-RS-IV improvement in the forced-titration arm. Stopping at 30 mg leaves a large portion of available therapeutic benefit on the table.

The American Academy of Pediatrics 2019 ADHD clinical practice guideline recommends titrating to the highest tolerated dose before concluding a stimulant trial has failed. [3] "Optimize medication dosage for each patient; dosage should not be based solely on body weight" is the direct language from that guideline.

Timing also matters. Lisdexamfetamine reaches peak plasma concentration (Tmax) at approximately 3.8 hours post-dose for d-amphetamine, compared with 1 hour for immediate-release amphetamine salts. [8] Patients comparing Vyvanse to prior IR stimulant experience sometimes perceive Vyvanse as "not working" because the onset is slower, not because the drug is less effective.

Side Effects That Masquerade as Non-Response

Some patients discontinue Vyvanse not because it fails to improve attention, but because the side-effect burden reduces their overall quality of life to a point where they prefer unmedicated ADHD. This is clinically distinct from non-response, though patients often describe it identically in reviews.

The most common adverse events in NRP104.301 affecting 5% or more of patients were: decreased appetite (27.1%), insomnia (13.1%), dry mouth (11.2%), headache (10.1%), and elevated blood pressure (5.8%). [1] Cardiovascular monitoring, baseline and follow-up pulse and BP, is recommended by the FDA label and the American Heart Association's 2008 scientific statement on stimulants in children and adults. [12]

Appetite suppression is the most common reason Drugs.com reviewers describe rating Vyvanse below 4 stars despite stating it "works" for ADHD. Eating a protein-rich meal before the first dose of the day and a second meal during the brief appetite window in the late afternoon largely mitigates this for most patients.

How Vyvanse Compares to Other First-Line ADHD Stimulants

Direct head-to-head trials are limited but informative.

The CDSMP study (N=129) compared lisdexamfetamine with mixed amphetamine salts extended release (Adderall XR) in adults over 6 weeks. Both drugs produced significant ADHD-RS-IV reductions, with lisdexamfetamine showing numerically higher response at week 6 (58% vs. 51% CGI-I responders) though the difference did not reach statistical significance (P=0.31). [13]

Methylphenidate-based medications show consistent meta-analytic effect sizes slightly below amphetamine-based medications in adults. A 2018 Lancet meta-analysis of 133 double-blind RCTs (N=10,068 adults) found amphetamines produced a standardized mean difference of 0.49 versus 0.37 for methylphenidate on clinician-rated ADHD scales. [14] Lisdexamfetamine was the most-studied amphetamine formulation in that dataset.

Interpreting "Vyvanse Stopped Working": Tolerance vs. Pseudotolerance

One of the most visited topics in r/VyvanseADHD is the perception that Vyvanse "stops working." Clinicians separate this into two categories.

True pharmacodynamic tolerance involves measurable receptor downregulation with sustained amphetamine exposure. Animal models confirm this mechanism, but human clinical data over 12 months show modest effect attenuation at most, roughly a 2.1-point ADHD-RS-IV drift per year in the SPD489-303 extension, which is small relative to the initial 16-point gain. [9]

Pseudotolerance is far more common and encompasses: worsening sleep quality reducing drug effectiveness, caffeine intake increasing baseline stimulation and narrowing the perceived delta, dose timing errors, weight gain requiring dose recalculation, or the reemergence of previously masked comorbidities. Most Reddit reports of "Vyvanse stopped working" resolve after a structured medication holiday (drug holiday) of 2 to 4 weeks, which would not be expected to resolve true receptor-level tolerance.

Prescribers reviewing for tolerance should obtain a repeat ADHD-RS-IV score, rule out new comorbidities, and audit sleep logs before concluding the drug has stopped working and escalating to a higher dose or switching agents.